Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CSL Vifor
The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.
Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.
The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.
Travere Therapeutics is aiming to provide a new foundational therapy for IgAN patients with its novel non-immunosuppressive agent, Filspari, as it prices it at a discount to Calliditas’s rival Tarpeyo, ahead of looming further competition.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Group, Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma
- Sanifit Therapeutics S.A.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.